title: Long-term survival of patients with metastatic renal cell carcinoma treated with pulsed dendritic cells.
abstract: OBJECTIVE
  This study aimed to determine the long-term survival of 30 dendritic cell (DC) vaccinated patients with metastatic renal cell cancer.
  
  
  METHODS
  Patients were treated with a therapeutic vaccination of pulsed DCs in one of three clinical phase I/II trials during the years 1999 - 2003.
  
  
  RESULTS
  Patients were followed up until 191 months (mean 65 days after DC therapy), when all patients had died. Total response to treatment was 40% with partial remission in 3%, mixed response in 7% and stable disease in 30%. The progressive disease rate was 60%. Long-term survival ranged from 3 to 191 months, with a mean survival of 59 months. Interestingly, patients who were treated previously with another form of immunotherapy showed a significantly improved probability of surviving. Mean long-term survival from the beginning of DC therapy was 21 months (1 to 75 months).
  
  
  CONCLUSIONS
  Patients treated with DC vaccination seem to have a benefit in long-term survival.
authors.affiliation: Center for Integrated Oncology (CIO), Department of Internal Medicine III, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Kraemer
authors.forename: Stefan
authors.initials: S
authors.lastname: Hauser
authors.forename: Ingo G H
authors.initials: IG
authors.lastname: Schmidt-Wolf
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000401:mortality* / Q000628:therapy; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000401:mortality* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D014611:Vaccination